With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some tough new realities.
A “large pharmaceutical customer” has ended its partnership with Cellares in a move “specific to” that company, Cellares co-founder and CEO Fabian Gerlinghaus revealed in a LinkedIn post over the weekend.
“The loss of this partnership requires us to resize the company,” Gerlinghaus said, without going into specifics on the amount or types of roles being eliminated.
He continued: “That means saying goodbye to talented colleagues who helped build Cellares and advance our mission,” adding that he was deeply grateful for their work at the company, which is now committed to helping affected staffers through the change. Gerlinghaus also invited anyone viewing the post on LinkedIn to reach out for a peek at the company’s resume book.
Cellares did not immediately respond to Fierce’s request for additional color on the layoff round and terminated partnership.
